Fascaplysin对ICR小鼠S180移植瘤的抑制作用及体内安全性的初步观察

中国临床药理学与治疗学 ›› 2010, Vol. 15 ›› Issue (11): 1206-1210.

Fascaplysin对ICR小鼠S180移植瘤的抑制作用及体内安全性的初步观察

徐炜烽¹, 王峰¹, 陈海敏², 卢晓玲², 严小军²

¹浙江省宁波市李惠利医院检验科,宁波 315041,浙江;
²宁波大学浙江省海洋生物工程重点实验室,宁波 315211, 浙江

收稿日期:2010-09-29 修回日期:2010-11-05 出版日期:2010-11-26 发布日期:2020-09-16
通讯作者: 陈海敏,女,博士,副研究员,研究方向:海洋生物。Tel: 0574-87609572 E-mail: haiminch75@yahoo.com.cn
作者简介:徐炜烽,男,本科,副主任技师,研究方向:检验医学。Tel: 0574-87018791 E-mail: nbxwf@sohu.com
基金资助:
国家自然科学基金项目(30800860)

Preliminary study on antitumor effects of Fascaplysin and safety in vivo in transplanted S180 tumor of ICR mice

XU Wei-feng¹, WANG Feng¹, CHEN Hai-min², LU Xiao-ling², YAN Xiao-jun²

¹Department of Laboratory, Lihuili Hospital of Ningbo, Ningbo 315041, Zhejiang, China;
²Key Laboratory of Marine Biotechnology, Ningbo University, Ningbo 315211, Zhejiang, China

Received:2010-09-29 Revised:2010-11-05 Online:2010-11-26 Published:2020-09-16

摘要/Abstract

摘要： 目的: 研究Fascaplysin对ICR小鼠移植性骨肉瘤S180瘤体的体内抑制作用。方法: 急性毒性实验采用LD₅₀数据处理程序1.01版计算LD₅₀。皮下注射技术建立荷S180骨肉瘤的ICR小鼠动物模型,并随机分为空白对照组 (注射生理盐水)、阳性对照组(CTX,30 mg·kg^-1·d^-1)、Fascaplysin 高剂量组(20 mg·kg^-1·d^-1)和Fascaplysin低剂量组(5 mg·kg^-1·d^-1)共4组,观察相应处理10 d后各组小鼠移植瘤生长状况(抑瘤率)及瘤组织病理学形态变化。结果: 阳性对照组、Fascaplysin高剂量组和Fascaplysin低剂量组的抑瘤率分别为(53±9)%、(52±10)%和(30±12)%;给药期间Fascaplysin对ICR小鼠肝、肾组织未产生明显的病理性影响,而对ICR小鼠体内S180移植瘤组织的病理性影响较为明显。结论: 一定剂量的Fascaplysin对ICR小鼠S180移植性骨肉瘤生长具有较好的抑制作用,是一个有潜力的抗癌药物。

关键词: Fascaplysin, ICR小鼠, S180, 抑瘤作用

Abstract: AIM: To study the inhibitory effect of Fascaplysin on the growth of transplanted S180 tumor in ICR mice. METHODS: The LD₅₀ was counted by LD₅₀ 1.01 software for acute toxicity test. Mouse models bearing S-180 tumor were established by subcutaneous injection in ICR mice, randomly divided into 4 groups: control group (injection of saline), positive control group (CTX, 30 mg·kg^-1·d^-1) , high dose group (Fascaplysin, 20 mg·kg^-1·d^-1) and low dose group (Fascaplysin, 5 mg·kg^-1·d^-1). The growth and histopathological changes of the tumors were observed 10 d after the corresponding treatment of all groups. RESULTS: The growth inhibition rates of positive control group, high dose group and low dose group were (53±9)%, (52±10)% and(30±12)%, respectively.Compared with the control group, there were no significant histopathological changes in liver and kidney of ICR mice during the administration of Fascaplysin, but there were significant changes in transplanted S180 tumor. CONCLUSION: A certain dose of Fascaplysin can significantly inhibit the growth of transplanted S180 tumor in ICR mice. It is a potential antitumor lead compound.

Key words: Fascaplysin, ICR mice, S180, Antitumor effect

中图分类号:

R965.2

徐炜烽, 王峰, 陈海敏, 卢晓玲, 严小军. Fascaplysin对ICR小鼠S180移植瘤的抑制作用及体内安全性的初步观察[J]. 中国临床药理学与治疗学, 2010, 15(11): 1206-1210.

XU Wei-feng, WANG Feng, CHEN Hai-min, LU Xiao-ling, YAN Xiao-jun. Preliminary study on antitumor effects of Fascaplysin and safety in vivo in transplanted S180 tumor of ICR mice[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(11): 1206-1210.

[1]	李丽华, 陈靠山, 喻丽珍, 卜晓阳. 拟康氏木霉胞外多糖抗肿瘤活性研究[J]. 中国临床药理学与治疗学, 2013, 18(3): 282-285.
[2]	郭维, 冉福香, 王瑞卿, 崔景荣, 李润涛, 程铁明, 葛泽梅. 4-甲基哌嗪-1-二硫代甲酸-(3-氰基-3, 3-二苯基)丙酯盐酸盐在小鼠的抗肿瘤作用[J]. 中国临床药理学与治疗学, 2004, 9(1): 59-62.
[3]	陈方, 吴铁, 傅玉萍, 刘晓青. 人参茎叶皂甙对5-氟脲嘧啶抗肿瘤的增强作用[J]. 中国临床药理学与治疗学, 2002, 7(4): 299-301.